

FYN, SARS-CoV-2, and IFITM3 in the neurobiology of Alzheimer's disease

Vavougiou, George D; Breza, Marianthi; Mavridis, Theodore; Krogfelt, Karen Angeliki

Published in:
Brain Disorders

DOI:
[10.1016/j.dscb.2021.100022](https://doi.org/10.1016/j.dscb.2021.100022)

Publication date:
2021

Document Version
Publisher's PDF, also known as Version of record

Citation for published version (APA):
Vavougiou, G. D., Breza, M., Mavridis, T., & Krogfelt, K. A. (2021). FYN, SARS-CoV-2, and IFITM3 in the neurobiology of Alzheimer's disease. *Brain Disorders*, 3(3), Article 100022.
<https://doi.org/10.1016/j.dscb.2021.100022>


General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

Take down policy

If you believe that this document breaches copyright please contact rucforsk@kb.dk providing details, and we will remove access to the work immediately and investigate your claim.



FYN, SARS-CoV-2, and IFITM3 in the neurobiology of Alzheimer's disease

George D. Vavougiou^{a,b,*}, Marianthi Breza^c, Theodore Mavridis^c, Karen Angeliki Krogfelt^{d,e}

^a Neuroimmunology Laboratory, Department of Neurology, Athens Naval Hospital, P.C. 115 21, Athens, Greece

^b Department of Computer Science and Telecommunications, University of Thessaly, Papasiopoulou 2 – 4, P.C. 35 131 – Galaneika, Lamia, Greece

^c 1st Department of Neurology, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece

^d Department of Science and Environment, Roskilde University, Universitetsvej 1, 28A.1, DK-4000 Roskilde Denmark

^e Molecular and Medical Biology, Roskilde University, Universitetsvej 1, 28A.1, DK-4000 Roskilde Denmark

ARTICLE INFO

Keywords:

Alzheimer's disease
Antimicrobial protection hypothesis
COVID-19
FYN Kinase
IFITM3
Type I Interferon
Innate immunity

ABSTRACT

Introduction: (IFITM3) is an innate immune protein that has been identified as a novel γ -secretase (γ s) modulator. FYN is a kinase that stabilizes IFITM3 on the membrane, primes APP for amyloidogenic γ s processing and mediates tau oligomerization. The purpose of this study is to explore the role of FYN and IFITM3 in AD and COVID-19, expanding on previous research from our group.

Methods: A 520 gene signature containing FYN and IFITM3 (termed Ia) was extracted from a previously published meta-analysis of Alzheimer's disease (AD) bulk- and single nuclei sequencing data. Exploratory analyses involved meta-analysis of bulk and single cell RNA data for IFITM3 and FYN differential expression per CNS site and cellular type. Confirmatory analyses, gene set enrichment analysis (GSEA) on Ia was performed to detect overlapping enriched biological networks between COVID-19 with AD.

Results: Bulk RNA data analysis revealed that IFITM3 and FYN were overexpressed in two CNS regions in AD vs. Controls: the temporal cortex Wilcoxon p-value=1.3e-6) and the parahippocampal cortex Wilcoxon p-value=0.012). Correspondingly, single cell RNA analysis of IFITM3 and FYN revealed that it was differentially expressed in neurons, glial and endothelial cells donated b AD patients, when compared to controls.

Discussion: IFITM3 and FYN were found as interactors within biological networks overlapping between AD and SARS-CoV-2 infection. Within the context of SARS-CoV-2 induced tau aggregation and interactions between tau and Ab1-42, the FYN – IFITM3 regulome may outline an important innate immunity element responsive to viral infection and IFN-I signaling in both AD and COVID-19.

1. Introduction

Interferon-induced transmembrane protein 3 (IFITM3) belongs to a family of proteins that act as a second line of defense against enveloped viruses, including SARS-CoV-2. IFITM3's role in intercepting and shuttling viral particles to the lysosomes[1] was recently complemented by its discovery as a novel γ -secretase modulator that promotes A β production[2]. Considering the accumulating evidence on common pathways between COVID-19 and Alzheimer's disease (AD)[3], we aimed to examine whether FYN, a kinase regulating IFITM3's membrane localization [4,5] is accordingly perturbed in both AD and COVID-19 transcriptomes. Current state of the art transcriptomic evidence suggest that FYN interacts with SARS-CoV-2 during the course of infection[6], and was found to be upregulated in a recent meta-analysis of SARS-CoV-2 expression datasets[7]. Expanding on our previous research on IFITM3

networks in AD[8] and their overlap with COVID-19 [9], we propose a comprehensive model of AD pathogenesis where viral induction of the IFITM3/FYN endocytosis signal could account for increased A β oligomerization via γ -secretase activation[2]. Furthermore, SARS-CoV-2 induced FYN dysregulation / overactivation [6,7] would concomitantly and independently promote Tau fibrilization[10], abrogate autophagy[4], and prepare APP[11] for processing by the previously IFITM3²-activated γ -secretase complex.

In order to explore FYN and IFITM3's expression patterns and networks in AD vs. COVID-19, we applied a composite systems biology approach[12]. Gene expression data from both bulk tissue and single cell RNA sequencing studies were used in order to explore FYN and IFITM3's expression patterns in CNS sites and cells beyond those examined by previous research from our group [8,9]. Subsequently, we aimed to investigate the overlap between FYN/IFITM3's biological

* Corresponding author at: , 70 Deinokratous Street, Athens, Greece.

E-mail address: gvavougiou@uth.gr (G.D. Vavougiou).

<https://doi.org/10.1016/j.dscb.2021.100022>

Received 4 May 2021; Received in revised form 15 August 2021; Accepted 16 August 2021

Available online 18 August 2021

2666-4593/© 2021 The Authors.

Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license

(<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

networks and SARS-CoV-2 infectomics. Finally, we provide data on FYN/IFITM3 networks that arose in our previous study and integrated them in a comprehensive model of AD and AD-like manifestations of NeuroCOVID-19's pathogenesis.

2. Methods

2.1. Data acquisition

For this study, we utilized consensus gene module and differential gene expression data on IFITM3 and FYN from a previously published [13] of AD brain transcriptomes. These datasets included data generated by the Accelerating Medicines Partnership Alzheimer's Disease Project (AMP-AD)[14] as well as publicly available datasets [15-17]; The AMP-AD datasets included RNA-seq provided by the Mayo Clinic Brain Bank[18], the Religious Orders Study and Memory and Aging Project (ROSMAP) [19] and the Mount Sinai School of Medicine (MSSM)[20] studies.

Consensus gene expression modules represent gene co-expression networks detected via consensus Weighted Gene Co-expression Network Analysis (cWGCNA)[21]. These networks contain highly correlated genes that are conserved across studies, and are furthermore associated with specific sample traits, such as cell type and diagnosis, and combined with other sources of data, such as single nuclei RNA-seq experiments and genome wide association studies (GWAS). For both genes of interest, module membership and the eigengene-based connectivity (k_{ME} ; range of values: -1 to 1) are reported according to primary data.

2.2. Reconstruction of the FYN – IFITM3 interactome and comparative transcriptomics with COVID-19 datasets

Consensus gene modules containing FYN and IFITM3 were considered as candidate interactomes, visualized via STRING (available from: <https://string-db.org> [22] and used for comparative gene set enrichment analyses (GSEA) via Enrichr[23] (Available from: (Available from: <https://maayanlab.cloud/Enrichr/>). Enrichment analyses aimed both to (a) determine the biological functions and pathways associated with FYN/IFITM3 signatures and (b) determine overlap with gene signatures extracted from COVID-19 datasets. For GSEA, adjusted p-values <0.05 were considered statistically significant.

2.3. Determination of IFITM3-FYN's cell- and CNS site- associations

Consensus gene modules represent gene co-expression networks that are conserved across datasets, CNS regions and enriched for specific states (i.e. upregulated in AD) and cell types[24]. In order to determine whether FYN and IFITM3's differential expression was region specific, we inquired each gene's comparative expression per study and CNS region (accessible via: <http://swaruplab.bio.uci.edu:3838/bulkRNA/>) [13]. Expression data were reported as reported as log2 transformed hub gene expression, with unpaired Wilcoxon test p-values <0.05 determining differential gene expression between AD vs. Controls.

While data on asymptomatic AD are also provided, we did not consider them in the context of determining FYN / IFITM3 associations with CNS sites in AD. Furthermore, it should be noted that differential gene expression were complimentary to the extraction of the FYN / IFITM3 interactome, as detailed previously.

2.4. Determination of FYN and IFITM3's cell- and disease- associations in AD via single cell RNA transcriptomics

For single-cell expression studies, the scREAD database (Available from: <https://bmbis.bmi.osumc.edu/scread/>) was interrogated, to further characterize FYN and IFITM3's expression in AD-donated cells and associated CNS regions [10,11]. The scREAD platform is a unique

database compiling single cell RNA sequencing (scRNA-Seq) data from AD studies along with matched control atlases. Furthermore, it provides differential gene expression data that account for gender, brain region, and age. Herein, we screened gene expression data from human datasets, and examined all cross-dataset, disease – control comparisons. For all comparisons, a gene was considered as differentially expressed when the independent samples Wilcoxon p-values <0.05 (Bonferroni adjusted) and the absolute value of the logFC in the single cell resolution was >0.25 [25].

2.5. Data availability statement

Primary data are available from their respective sources, as cited herein. All data meta-data generated by the analyses in this manuscript are available online via Mendeley Data (Available from: <https://data.mendeley.com/datasets/5bypp2h5kj/1>) and as supplementary files.

3. Results

3.1. Reconstruction of the FYN – IFITM3 interactome, its associations with AD and cell types

Both FYN ($k_{ME} = 0.87$) and IFITM3 ($k_{ME} = 0.77$) were detected in a consensus module (CM9; $n_{genes} = 520$) that was positively correlated with AD diagnosis, significantly enriched in astrocytes and endothelial cells, and methylation quantitative trait loci (mQTL)[13]. This FYN/IFITM3 containing module was used as a candidate interactome (henceforth dubbed I_a ; Fig. 1) and was subsequently used in GSEA.

Analysis of bulk RNA data revealed that IFITM3 was overexpressed in two regions in the discovery datasets: the temporal cortex (TC; Mayo Clinic Study, AD vs. Controls, Wilcoxon test p-value = $1.3e^{-6}$) and the parahippocampal gyrus (PHCG; MSSM study, AD vs. controls, Wilcoxon test p-value = 0.012); (Supplementary Fig. 1a). In the validation datasets, IFITM3 was differentially expressed in Zhang et al's study [9] (AD vs. Controls, Wilcoxon test p-value $<2.2e^{-6}$; Supplementary Fig. 1b). FYN was differentially expressed in the temporal cortex (Mayo Clinic Study, AD vs. Controls, adj. p-value = $2.9e^{-5}$), the prefrontal cortex (PFC; ROSMAP Study, AD vs. Controls, Wilcoxon test p-value = 0.004) and the parahippocampal gyrus (MSSM study, AD vs. controls, Wilcoxon test p-value = $2.9e^{-5}$); Supplementary Fig. 1c. In the validation datasets, FYN was differentially expressed in two datasets, including Zhang et al's study [13] (AD vs. Controls, Wilcoxon test p-value $<2.2e^{-16}$; Supplementary Fig 1d). Taken together, these results indicate that the over-expression of FYN and IFITM3 can be localized to the PFC, the TC and the PHCG (Fig. 1 and Supplementary Materials 1_{a-d}).

3.2. FYN and IFITM3's cell- and disease- associations in AD via single cell RNA transcriptomics

Cross-dataset comparisons of the scREAD database revealed that IFITM3 and FYN were differentially expressed in AD when compared to controls (adj. p-value <0.05) in a cell-type and CNS site-specific manner (Figs. 2 and 3)

Specifically, that IFITM3 was overexpressed (a) in astrocytes, microglia and endothelial cells in the entorhinal cortex datasets (b) underexpressed astrocytes, microglia and endothelial cells and oligodendrocyte precursor cells in the prefrontal cortex datasets (d) overexpressed in microglia the superior parietal lobe datasets AD01203, AD01204 and underexpressed in microglia from the superior parietal lobe dataset AD01205 (Supplementary Materials 2a,b).

FYN was differentially expressed in astrocytes, microglia, oligodendrocytes, oligodendrocyte precursors, endothelial cells, excitatory and inhibitory neurons in the entorhinal cortex, prefrontal cortex and the superior frontal gyrus. No clear pattern of differential expression (ubiquitously up or down) could be established between cell types or CNS regions, indicating significant cell-to-cell variability[25]




Fig. 2. Schematic representation of central nervous sites associated with the overexpression of FYN and IFITM3, i.e. the prefrontal cortex, the temporal cortex and the parahippocampal gyrus.

superior parietal lobe and the parahippocampal gyrus. FYN was differentially expressed in glial, endothelial cells and neurons in the entorhinal cortex, the prefrontal cortex and the superior frontal cortex, and its expression was characterized by high cell-to-cell variability.

Based on our findings, we will review the state-of-the-art regarding the role of FYN and IFITM3 in the pathobiology of AD. Furthermore, we will discuss the role of immune processes in tau and A β processing, and its potential perturbations. Finally, we will synthesize our findings and the literature in a quasinfected hypothesis on AD pathogenesis that may be applicable to the newly emerging COVID-19 associated dyscognitive disorder.

4.1. FYN / IFITM3 pathways in Alzheimer's disease and innate immunity

The recent identification of IFITM3, an established antiviral factor as a gamma secretase modulator[2] has provided deeper foundations to the antimicrobial protection hypothesis of AD pathogenesis[26]. Our focus on FYN is founded on its regulatory role in stabilizing IFITM3 in the membrane via phosphorylation of a critical motif[5], enabling its potential interaction with the gamma secretase complex. Notably, FYN has been shown to phosphorylate APP in AD neurons, a process that enhances its amyloidogenic processing[11]. Notably, oligomeric A β can upregulate FYN by interacting with PrP^c-mGluR5[27] inducing FYN-mediated phosphorylation of NMDA receptors[28]. Taken together, these studies indicate that FYN may regulate IFITM3 – gamma secretase – APP amyloidogenic processing via phosphorylation, with A β -PrP^c-mGluR5 cascades providing a feed-forward loop at the autocrine and paracrine milieu.

Aside from A β oligomerization, FYN has been shown to mediate tau aggregation *in vivo*[10], with process that involve both direct phosphorylation and activation of other kinases such as GSK-3 β via NMDAR activation[27]. Notably, GSK-3 β activation can lead to both FYN's activation and altered subcellular localization, either (a) in the plasma membrane, constituting a feedback loop GSK3- β -FYN—NMDAR-GSK-3 β feedback loop) or in other subcellular compartments, including the nucleus [29,30].

Within the context of the antimicrobial protection hypothesis, both

IFITM3 and FYN offer unique insight in the interactions between viral modulations of the transcriptome, innate immunity and AD pathology. We have previously shown that IFITM3 gene signatures enriched for IFN-I signaling represent overlapping pathways between AD and COVID-19[9]. IFITM3's role in SARS-CoV-2 has been shown to be structure dependent. Specifically, mutational alterations of its Yxx Φ motif, FYN's phosphorylation target, may maintain the balance between SARS-CoV-2's restriction or permission[31]. To our knowledge, we are the first to outline this functional relationship in the literature. Furthermore, mutational ablation of this site indicates that SARS-CoV-2-IFITM3 mediated entry may be mediated by hijacking of IFITM3's endocytic signal[32], a concept that has recently been corroborated[33].

FYN's role in cytokine signaling is upstream compared to IFITM3's, positively regulating (i.e. proinflammatory) signal transduction following immune receptor activation[34]. This *modus operandi* has been observed in microglia in animal models of Parkinson's disease[35]. Aside from its homeostatic role, FYN may be recruited in viral processes that require phosphorylation[36] and subversion of specific compartments such as autophagosomes[37]. In SARS-CoV-2, FYN has been reported as a differentially expressed gene via multiple omics approaches [7,6] albeit the consequences of its recruitment or perturbation have not been explored.

4.2. SARS-CoV-2-related neurocognitive deficits and their importance in AD pathobiology: from phenotypes to genes

COVID-19 has been lately recognized as a spectrum, one that includes both phenotypic and genomic overlap with neurodegenerative disease including Alzheimer's disease[38]. Among the more albeit easily underdiagnosed manifestations are neurocognitive symptoms, including memory defects, even among those patients recovered from mild disease [39].

A study reporting on a 3-month follow-up of patients recovering from COVID-19 uncovered microstructural alterations in the entorhinal cortex, associated with hyposmia, whereas memory loss was associated with hippocampal cortex remodeling[40]. As a previous hypothesis from our group[41], this concept has been subsequently validated by neuropathological studies that have detected SARS-CoV-2 in the olfactory cortex and the hippocampi [42,43]. Notably, a primate model of SARS-CoV-2 neurotropism has provided further corroboration to the our previously stated hypothesis[44].

Aside from the phenotypical overlap, genetic and epigenetic mechanisms have been shown to overlap between Alzheimer's disease and COVID-19. Independent meta-analyses of gene expression data have corroborated IFITM3 as a commonly perturbed gene in both conditions [45,46]. In the setting of SARS-CoV-2 infection, single nuclei RNA sequencing has identified FYN and IFITM3 perturbations spatially linked them to blood-barrier endothelial and glial cells[47]. A link between SARS-CoV-2 and the secretory phenotype of senescent endothelial cells has recently identified IFITM3 downregulation as a result of paracrine cellular communication[48]. Fisetin, a senolytic that has been shown to improve cognition and soluble A β burden[49], was used in the previous study to upregulate IFITM3 and reduce senescent cell burden[48].

Taken together, these studies outline known and interdependent connections of FYN and IFITM3 with innate immunity, viral lifecycles and the pathophysiological processes underlying AD.

4.3. Fitting SARS-CoV-2 in the antimicrobial protection hypothesis of Alzheimer's disease: a demi-infectious hypothesis

Several recent studies have bolstered the concepts underlying the antimicrobial protection hypothesis[26]. Soluble A β has been shown to function as an opsonin-like molecule, forming complexes with nucleic acids (both endogenous and viral) and enhancing their recognition by glial, while upregulating IFITM3-containing IFN-I signatures[50]. This




Fig. 3. IFITM3 and FYN in the setting of a deminfectious hypothesis of Alzheimer's disease pathogenesis, with SARS-CoV-2 as the pathogen. Lipid-raft mediated SARS-CoV-2 endocytosis in lipid rafts leads to a SARS-CoV-2 – IFITM3 interaction and endosomal sequestration (1). Depending on the phosphorylation status of IFITM3, the virus is either sequestered in IFITM3-enriched endosomes (2a) or retained in the surface (2b). Successful clearance of an invading virus via endosome – lysosome fusion leads to the recognition of viral fragments as DAMPs by PRRs such as RIG-I / MDA-5, which mediate upregulate IFN-I genes. IFN-I responses can function in an autocrine manner via their receptors (4a) and via STAT3 signaling, provide positive feedback of IFITM3's expression in IFN-I primed cells, or induce its expression in naïve cells. Notably, FYN has been shown to promote STAT3 signaling as part of proinflammatory priming of peripheral immune cells and microglia. IFITM3 mediates IRF3 autosomal degradation (not shown here), introducing a negative feedback loop in DAMP recognition. Viruses that escape endosomal sequestration or capitalize mutant IFITM3 isoforms, as has been shown in SARS-CoV-2, may escape and replicate productively (5a), recruiting host kinases. Tau hyperphosphorylations may occur as a result of viral processes, culminating in toxicity and oligomerization (6a). In the alternative scenario of IFITM3 phosphorylation, the latter becomes stabilized on the membrane, priming gamma secretase (3b), and A β oligomer release in the paracrine milieu (4b). Concomitant phosphorylation of APP by FYN completes amyloidogenic priming (3b), and A β oligomer release in the paracrine milieu (4b). Isoform-specific interactions between A β oligomers and SARS-CoV-2's S1 have been reported, and may alter its infectivity; A β_{1-42} in particular has been shown to promote rather than abrogate S1-ACE2 interactions (5b), and facilitate canonical SARS-CoV-2 entry (6b). Autocrine A β -PrP^c interactions provide further feedback to FYN via phosphorylation targets such as mGluR5 (3c). Physical interactions between FYN and NMDAR link A β and tau pathology via the activation of multiple kinases (indirectly, following calcium influx), the direct activation of GSK-3 β , or FYN-mediated tau oligomerization.

non-specific mechanism of recognizing danger-associated molecular patterns (DAMPs) represents a sentinel aspect of innate immunity that is fundamentally perturbed in the setting of AD[51]. DAMP dysregulation in AD furthermore extends to other pattern-recognition receptors (PRR), such retinoic acid-inducible gene-1 (RIG-1), and feeds back to A β production[52].

Recognition of invading viruses, including SARS-CoV-2, by RIG-I/MDA5 is followed by an IRF3 mediated induction of IFN- β . Autocrine and paracrine IFN- β induction would upregulate IFITM3 and enhance its trafficking in endosomes and the membrane[53]. While this is physiologically this represents an antiviral mechanism, SARS-CoV-2's ORF3a has been shown to block lysosomal fusion and may thus escape into the cytosol [54,55]. furthermore, FYN-mediated enhancement of STAT3 cascades would enhance this feedback loop and maintain proinflammatory signaling[56]. Up to this point, viral invasion, global and cell-level IFN-I signaling represents a common niche between AD and COVID-19 [50,57]. FYN dysregulation at this point may contribute to global IFN-I perturbations via proinflammatory signaling[34] in peripheral immune cells [58,59]. Alternatively, FYN has been shown to enhance neuroinflammation in AD, Parkinson's disease dementia (PDD) and Dementia with Lewy bodies (DLB) by maintaining proinflammatory signaling microglia, associated with increased A β and pTau and dysproteostasis[60]. This paradigm of peripheral and CNS immune perturbations in AD has been recently outlined in an extended IFITM3 gene signature including OAS1, and overlapping with transcriptome

perturbations in COVID-19[61]. Beyond SARS-CoV-2, interferon-related genes such as OAS1 [62] and IFITM3[2] and downstream signal modulators such as FYN[34] are key players in both AD and susceptibility to wide variety of such as HIV-1 [63], WNV[64] and DENV[65].

IFITM3's recent addition as a gamma secretase modulator[2] further raises the question of context, in its interaction with a HSV-1[66] and HSV-1's rapid seeding by A β as a potentially protective mechanism[67]. Notably, in silico analyses have indicated that the previously mentioned model can be realized by SARS-CoV-2; it's S1 has high affinity for soluble A β and tau [68]. This novel interaction has been shown to be isoform specific, with A β_{1-42} enhancing rather abrogating infectivity by modulating ACE2-S1 interactions[69].

Within this context, FYN dysregulation can link A β accumulation, Tau hyperphosphorylation and innate immunity in the setting of COVID-19. SARS-CoV-2 infection experiments with brain organoids have recently revealed that neuroinvasion is followed by altered neuronal distribution of hyperphosphorylated Tau[70]. Furthermore, data from SARS-CoV-2 infectomics have consistently outlined the induction of the tau kinase pathway and impaired autophagy following SARS-CoV-2 neuroinvasion[71]. Via both direct and indirect mechanisms, FYN perturbations could account for SARS-CoV-2 -induced tau aggregation[10]. FYN-mediated stabilization of IFITM3 on the membrane would serve to prime its interactions with gamma secretase[2] along with amyloidogenic APP phosphorylation[11], and abort viral entry via endosomal escape[31]. FYN-enhanced A β -autocrine signaling would promote tau

Table 1
Significantly enriched COVID-19 datasets.

Index	Name	P-value	Adjusted p-value
1	500 genes up-regulated by SARS-CoV-2 in human Organoids cells from GSE154613	1.001e-19	4.474e-17
2	Top 500 upregulated genes for SARS-CoV-2 infection in human sclera from GSE164073	1.477e-18	3.301e-16
3	Top 500 up genes for SARS-CoV-2 infection 48 hpi in human alveolar organoids for GSE152586	9.499e-18	1.061e-15
4	500 genes up-regulated by SARS-CoV-2 in human Lung Organoid cells at 24 hpi from GSE148697	6.699e-17	4.991e-15
5	Top 500 upregulated genes for SARS-CoV-2 infection in human lung organoids from GSE148697	6.699e-17	4.991e-15
6	500 genes up-regulated by SARS-CoV-2 in human Calu3 cells at 24 h from GSE148729 s1 polyA	1.061e-15	5.926e-14
7	500 top upregulated genes from SARS-CoV-2 infection at 72 HPI from GSE157852	1.995e-14	9.189e-13
8	SARS-CoV perturbation; 402 Up Genes from GEN3VA; Human bronchial epithelial 2B4 cells; Accession: GSE17400 Platform: GPL570; Entry 6	2.469e-14	9.647e-13
9	500 genes up-regulated by SARS-CoV-2 in human pancreatic organoids from GSE151803	3.327e-13	7.435e-12
10	500 genes up-regulated by SARS-CoV-2 in human pancreatic organoids from GSE151803	3.327e-13	7.435e-12

toxicity [28,60], and prepare an A β -enriched antiviral milieu that would intercept incoming viruses via opsonin-like interactions [71] that prime microglia and provide feedback to IFN-I and IFITM3 specifically [50].

How would this local immune stimulation translate into a network-expanding neurodegenerative disease? Brain endothelial cells and glia cells could be the prime culprits in SARS-CoV-2, a concept supported by both our current findings and others [72]. Neuroinvasion and trans-olfactory spread of SARS-CoV-2 to the hippocampi, supported by the clinicoradiological course of COVID-19 dyscognitive syndromes [40] and neuropathology [42,44] would then represent the clinically evident stage. As we have previously proposed, at the neuroinvasion stage, a primary hub such as the olfactory cortex could inform its distal connectome of an invader and glia via the efflux of A β and Tau [9]. In the setting of the neuroimmune hypothesis, both these molecules would have to be reconsidered as a novel class of immune mediator that functions as a “blind” guardian in innate immunity signaling [71], following DAMP recognition by PPRs. A comprehensive model is presented in Figure 3.

4.4. Limitations and context

Our current work should be considered within its limitations and context. Currently, no study has evaluated the longitudinal development of pathologically proven AD following exposure to COVID-19, and such a study is required to verify both our findings and our hypotheses.

A study that combines Another important limitation is that other AD-related genes are also implicated in COVID-19 infection, such as APOE [73] and ACE2 [74]. While this implication further bolsters SARS-CoV-2's potential role in AD pathogenesis, genetic variability and gene interactions between these genes and the FYN/IFITM3 switch should be studied in detail, in order to elucidate their mechanistic effects. Cell-to-cell variability, as it arose in our scRNA-seq scrutiny of AD vs. Controls data, is another confounding factor in interpreting our results. This variability indicates the departure from the concept of tissues as homogenates, and the recognition of their heterogeneity. This paradigm has been acknowledged in microglia, along with its potential contribution to AD [75], and may furthermore indicate the need to account for senescence and the PASP phenotype in general in tissues [48].

Another limitation in our study is that the differential expression data from Morabito et al [13] only provide the p-values for pairwise comparisons and not raw data. As such, the direction of differential expression is derived from studying the plots, rather than the output. As both FYN and IFITM3 are a priori selected in a consensus gene module, this limitation does not affect their implication in AD or the validity of the interactome.

5. Conclusions

FYN represents a known modulator of IFITM3's stabilization in the membrane and its endocytic pathway. In this analysis, we determine the function, cell-, CNS-site specific context of their interaction within cytokine signaling in AD. Furthermore, we are the first to propose a deminfectious model of AD pathogenesis that can be initiated by SARS-CoV-2, building upon our previous research and contemporary knowledge. Future studies should aim to link clinical, radiological and neuropathological findings with genomics and basic science in order to fully characterize both the emerging entity of COVID-19 dyscognitive syndromes, and their implication in AD.

Author contributions

Conceptualization, analyses, first draft, final draft, revisions: GDV. Final draft, confirmation of analyses: TM, MB; Revisions, conceptualization: KAK. All authors have read and approved of the final draft. TM and MB contributed equally.

Declaration of Competing Interest

None declared.

Acknowledgments

To Dr Sofia Nikou, for timely revisions on this manuscript. To the late professor Robert Moir, a pioneer and visionary whose work inspired our own.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at [doi:10.1016/j.dscb.2021.100022](https://doi.org/10.1016/j.dscb.2021.100022).

References

- [1] C. Iadecola, J. Anrather, H. Kamel, Effects of COVID-19 on the nervous system, *Cell* 183 (2020) 16–27, <https://doi.org/10.1016/j.cell.2020.08.028>, e11.
- [2] J.-Y. Hur, et al., The innate immunity protein IFITM3 modulates γ -secretase in Alzheimer's disease, *Nature* 586 (2020) 735–740, <https://doi.org/10.1038/s41586-020-2681-2>.
- [3] M.A. Rahman, K. Islam, S. Rahman, M. Alamin, Neurobiochemical cross-talk between COVID-19 and Alzheimer's disease, *Mol. Neurobiol.* 58 (2021) 1017–1023, <https://doi.org/10.1007/s12035-020-02177-w>.
- [4] N.M. Chesarino, T.M. McMichael, J.C. Hach, J.S. Yount, Phosphorylation of the antiviral protein interferon-inducible transmembrane protein 3 (IFITM3) dually regulates its endocytosis and ubiquitination, *J. Biol. Chem.* 289 (2014) 11986–11992, <https://doi.org/10.1074/jbc.M114.557694>.
- [5] R. Jia, et al., The N-terminal region of IFITM3 modulates its antiviral activity by regulating IFITM3 cellular localization, *J. Virol.* 86 (2012) 13697–13707, <https://doi.org/10.1128/jvi.01828-12>.
- [6] S.S.S.J. Ahmed, et al., Regulatory cross talk between SARS-CoV-2 receptor binding and replication machinery in the human host, *Front. Physiol.* 11 (2020) 802.
- [7] B. Vastrad, C. Vastrad, A. Tengli, Identification of potential mRNA panels for severe acute respiratory syndrome coronavirus 2 (COVID-19) diagnosis and treatment using microarray dataset and bioinformatics methods, *3 Biotech.* 10 (2020) 422, <https://doi.org/10.1007/s13205-020-02406-y>.
- [8] G.D. Vavougiou, et al., Double hit viral parasitism, polymicrobial CNS residency and perturbed proteostasis in Alzheimer's disease: a data driven, in silico analysis of gene expression data, *Mol. Immunol.* 127 (2020) 124–135, <https://doi.org/10.1016/j.molimm.2020.08.021>.
- [9] G.D. Vavougiou, et al., Outside-in induction of the IFITM3 trafficking system by infections, including SARS-CoV-2, in the pathobiology of Alzheimer's disease,

- Brain Behav. Immun. Health 14 (2021), 100243, <https://doi.org/10.1016/j.bbimh.2021.100243>.
- [10] A. Briner, J. Götz, J.C. Polanco, Fyn Kinase controls Tau Aggregation In Vivo, *Cell Rep.* 32 (2020), 108045, <https://doi.org/10.1016/j.celrep.2020.108045>.
- [11] F. Iannuzzi, et al., Fyn Tyrosine Kinase elicits amyloid precursor protein Tyr682 phosphorylation in neurons from Alzheimer's disease patients, *Cells* 9 (2020), <https://doi.org/10.3390/cells9081807>.
- [12] D. Zella, et al., The importance of genomic analysis in cracking the coronavirus pandemic, *Expert Rev. Mol. Diagn.* 21 (2021) 547–562, <https://doi.org/10.1080/14737159.2021.1917998>.
- [13] S. Morabito, E. Miyoshi, N. Michael, V. Swarup, Integrative genomics approach identifies conserved transcriptomic networks in Alzheimer's disease, *Hum. Mol. Genet.* 29 (2020) 2899–2919, <https://doi.org/10.1093/hmg/ddaa182>.
- [14] R.J. Hodes, N. Buckholtz, Accelerating medicines partnership: Alzheimer's Disease (AMP-AD) knowledge portal Aids Alzheimer's drug discovery through open data sharing, *Expert Opin. Ther. Target.* 20 (2016) 389–391, <https://doi.org/10.1517/14728222.2016.1135132>.
- [15] B. Zhang, et al., Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease, *Cell* 153 (2013) 707–720, <https://doi.org/10.1016/j.cell.2013.03.030>.
- [16] N.C. Berchtold, et al., Synaptic genes are extensively downregulated across multiple brain regions in normal human aging and Alzheimer's disease, *Neurobiol. Aging* 34 (2013) 1653–1661, <https://doi.org/10.1016/j.neurobiolaging.2012.11.024>.
- [17] J.A. Webster, et al., Genetic control of human brain transcript expression in Alzheimer disease, *Am. J. Hum. Genet.* 84 (2009) 445–458, <https://doi.org/10.1016/j.ajhg.2009.03.011>.
- [18] M. Allen, et al., Human whole genome genotype and transcriptome data for Alzheimer's and other neurodegenerative diseases, *Sci. Data* 3 (2016), <https://doi.org/10.1038/sdata.2016.89>, 160089–160089.
- [19] S. Mostafavi, et al., A molecular network of the aging human brain provides insights into the pathology and cognitive decline of Alzheimer's disease, *Nat. Neurosci.* 21 (2018) 811–819, <https://doi.org/10.1038/s41593-018-0154-9>.
- [20] M. Wang, et al., The Mount Sinai cohort of large-scale genomic, transcriptomic and proteomic data in Alzheimer's disease, *Sci. Data* 5 (2018), 180185, <https://doi.org/10.1038/sdata.2018.185>.
- [21] P. Langfelder, S. Horvath, WGCNA: An R package for weighted correlation network analysis, *BMC Bioinform.* 9 (2008) 559, <https://doi.org/10.1186/1471-2105-9-559>.
- [22] D. Szklarczyk, et al., The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets, *Nucleic. Acids. Res.* 49 (2021) D605–d612, <https://doi.org/10.1093/nar/gkaa1074>.
- [23] M.V. Kuleshov, et al., Enrichr: a comprehensive gene set enrichment analysis web server 2016 update, *Nucleic. Acids. Res.* 44 (2016) W90–W97, <https://doi.org/10.1093/nar/gkw377>.
- [24] V. Swarup, et al., Identification of conserved proteomic networks in neurodegenerative dementia, *Cell Rep.* 31 (2020), 107807, <https://doi.org/10.1016/j.celrep.2020.107807>.
- [25] J.A. Hoffman, B.N. Pappas, K.W. Trotter, T.K. Archer, Single-cell RNA sequencing reveals a heterogeneous response to Glucocorticoids in breast cancer cells, *Commun. Biol.* 3 (2020) 126, <https://doi.org/10.1038/s42003-020-0837-0>.
- [26] R.D. Moir, R. Lathé, R.E. Tanzi, The antimicrobial protection hypothesis of Alzheimer's disease, *Alzheimers Dement.* 14 (2018) 1602–1614, <https://doi.org/10.1016/j.jalz.2018.06.3040>.
- [27] B. Penke, M. Szűcs, F. Bogár, Oligomerization and conformational change turn monomeric β -Amyloid and Tau proteins toxic: their role in Alzheimer's pathogenesis, *Molecules* 25 (2020), <https://doi.org/10.3390/molecules25071659>.
- [28] J.W. Um, S.M. Strittmatter, Amyloid- β induced signaling by cellular prion protein and Fyn kinase in Alzheimer disease, *Prion* 7 (2013) 37–41, <https://doi.org/10.4161/pri.22212>.
- [29] S. Mondragón-Rodríguez, G. Perry, X. Zhu, J. Boehm, Amyloid Beta and tau proteins as therapeutic targets for Alzheimer's disease treatment: rethinking the current strategy, *Int. J. Alzheimers Dis.* 2012 (2012), 630182, <https://doi.org/10.1155/2012/630182>.
- [30] J. Pan, et al., Triptolide induces oxidative damage in NRK-52E cells through facilitating Nrf2 degradation by ubiquitination via the GSK-3 β /Fyn pathway, *Toxicol. in Vitro* 58 (2019) 187–194, <https://doi.org/10.1016/j.tiv.2019.03.032>.
- [31] G. Shi, et al., Opposing activities of IFITM proteins in SARS-CoV-2 infection, *EMBO J.* 40 (2021), e106501, <https://doi.org/10.15252/embj.2020106501>.
- [32] N. Murgolo, et al., SARS-CoV-2 tropism, entry, replication, and propagation: considerations for drug discovery and development, *PLoS Pathog.* 17 (2021), e1009225, <https://doi.org/10.1371/journal.ppat.1009225>.
- [33] C. Prelli Bozzo, et al., IFITM proteins promote SARS-CoV-2 infection and are targets for virus inhibition in vitro, *Nat. Commun.* 12 (2021) 4584, <https://doi.org/10.1038/s41467-021-24817-y>.
- [34] S.B. Mkhaddem, et al., Lyn and Fyn function as molecular switches that control immunoreceptors to direct homeostasis or inflammation, *Nat. Commun.* 8 (2017) 246, <https://doi.org/10.1038/s41467-017-00294-0>.
- [35] N. Panicker, et al., Fyn Kinase regulates microglial neuroinflammatory responses in cell culture and animal models of Parkinson's disease, *J. Neurosci.* 35 (2015) 10058–10077, <https://doi.org/10.1523/jneurosci.0302-15.2015>.
- [36] M. de Wispelaere, A.J. LaCroix, P.L. Yang, The small molecules AZD0530 and dasatinib inhibit dengue virus RNA replication via Fyn kinase, *J. Virol.* 87 (2013) 7367–7381, <https://doi.org/10.1128/jvi.00632-13>.
- [37] R. Kumar, T. Agrawal, N.A. Khan, Y. Nakayama, G.R. Medigeshi, Identification and characterization of the role of c-terminal Src kinase in dengue virus replication, *Sci. Rep.* 6 (2016) 30490, <https://doi.org/10.1038/srep30490>.
- [38] G.A. de Erausquin, et al., The chronic neuropsychiatric sequelae of COVID-19: the need for a prospective study of viral impact on brain functioning, *Alzheimers Dement.* 17 (2021) 1056–1065, <https://doi.org/10.1002/alz.12255>.
- [39] M.S. Woo, et al., Frequent neurocognitive deficits after recovery from mild COVID-19, *Brain Commun.* 2 (2020) fcaa205, <https://doi.org/10.1093/braincomms/fcaa205>.
- [40] Y. Lu, et al., Cerebral micro-structural changes in COVID-19 patients - an MRI-based 3-month follow-up study, *EclinicalMedicine* 25 (2020), 100484, <https://doi.org/10.1016/j.eclinm.2020.100484>.
- [41] G.D. Vavougiou, Potentially irreversible olfactory and gustatory impairments in COVID-19: indolent vs. fulminant SARS-CoV-2 neuroinfection, *Brain Behav. Immun.* 87 (2020) 107–108, <https://doi.org/10.1016/j.bbi.2020.04.071>.
- [42] J. Meinhardt, et al., Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19, *Nat. Neurosci.* 24 (2021) 168–175, <https://doi.org/10.1038/s41593-020-00758-5>.
- [43] M. Pacheco-Herrero, et al., Elucidating the Neuropathologic Mechanisms of SARS-CoV-2 Infection, *Front. Neurol.* 12 (2021) 444.
- [44] L. Jiao, et al., The olfactory route is a potential way for SARS-CoV-2 to invade the central nervous system of rhesus monkeys, *Signal Transduct. Target. Ther.* 6 (2021) 169, <https://doi.org/10.1038/s41392-021-00591-7>.
- [45] Y. Zhou, et al., Network medicine links SARS-CoV-2/COVID-19 infection to brain microvascular injury and neuroinflammation in dementia-like cognitive impairment, *Alzheimers Res. Ther.* 13 (2021) 110, <https://doi.org/10.1186/s13195-021-00850-3>.
- [46] D. Blanco-Melo, et al., Imbalanced host response to SARS-CoV-2 drives development of COVID-19, *Cell* 181 (2020) 1036–1045, <https://doi.org/10.1016/j.cell.2020.04.026>, e1039.
- [47] A.C. Yang, et al., Dysregulation of brain and choroid plexus cell types in severe COVID-19, *Nature* 595 (2021) 565–571, <https://doi.org/10.1038/s41586-021-03710-0>.
- [48] C.D. Camell, et al., Senolytics reduce coronavirus-related mortality in old mice, *Science* 373 (2021) eabe4832, <https://doi.org/10.1126/science.abe4832>.
- [49] A. Currais, et al., Modulation of p25 and inflammatory pathways by fisetin maintains cognitive function in Alzheimer's disease transgenic mice, *Aging Cell* 13 (2014) 379–390, <https://doi.org/10.1111/acer.12185>.
- [50] E.R. Roy, et al., Type I interferon response drives neuroinflammation and synapse loss in Alzheimer disease, *J. Clin. Invest.* 130 (2020) 1912–1930, <https://doi.org/10.1172/jci133737>.
- [51] A. Chiarini, U. Armato, P. Hu, I. Dal Prà, Danger-sensing/pattern recognition receptors and neuroinflammation in Alzheimer's disease, *Int. J. Mol. Sci.* 21 (2020), <https://doi.org/10.3390/ijms21239036>.
- [52] J.P. de Rivero Vaccari, et al., RIG-I receptor expression in the pathology of Alzheimer's disease, *J. Neuroinflamm.* 11 (2014) 67, <https://doi.org/10.1186/1742-2094-11-67>.
- [53] T.M. McMichael, M. Chemudupati, J.S. Yount, A balancing act between IFITM3 and IRF3, *Cell. Mol. Immunol.* 15 (2018) 873–874, <https://doi.org/10.1038/cmi.2017.18>.
- [54] Y. Zhang, et al., The SARS-CoV-2 protein ORF3a inhibits fusion of autophagosomes with lysosomes, *Cell Discov.* 7 (2021) 31, <https://doi.org/10.1038/s41421-021-00268-z>.
- [55] M. Bianchi, A. Borsetti, M. Ciccozzi, S. Pascarella, SARS-CoV-2 ORF3a: mutability and function, *Int. J. Biol. Macromol.* 170 (2021) 820–826, <https://doi.org/10.1016/j.ijbiomac.2020.12.142>.
- [56] J. Yu, et al., FYN promotes gastric cancer metastasis by activating STAT3-mediated epithelial-mesenchymal transition, *Transl. Oncol.* 13 (2020), 100841, <https://doi.org/10.1016/j.tranon.2020.100841>.
- [57] J.S. Lee, E.-C. Shin, The type I interferon response in COVID-19: implications for treatment, *Nat. Rev. Immunol.* 20 (2020) 585–586, <https://doi.org/10.1038/s41577-020-00429-3>.
- [58] S. Dallari, et al., Src family kinases Fyn and Lyn are constitutively activated and mediate plasmacytoid dendritic cell responses, *Nat. Commun.* 8 (2017) 14830, <https://doi.org/10.1038/ncomms14830>.
- [59] S.E. Byeon, et al., The Role of Src Kinase in macrophage-mediated inflammatory responses, *Mediat. Inflamm.* 2012 (2012), 512926, <https://doi.org/10.1155/2012/512926>.
- [60] C.Y.B. Low, et al., Isoform-specific upregulation of FynT kinase expression is associated with tauopathy and glial activation in Alzheimer's disease and Lewy body dementias, *Brain Pathol.* 31 (2021) 253–266, <https://doi.org/10.1111/bpa.12917>.
- [61] N. Magusali, et al., Genetic variability associated with OAS1 and expression in myeloid cells increases the risk of Alzheimer's disease and severe COVID-19 outcomes, *bioRxiv* 2021 (2021), 435702, <https://doi.org/10.1101/2021.03.16.435702>, 2003.
- [62] D.A. Salihi, et al., Genetic variability in response to amyloid beta deposition influences Alzheimer's disease risk, *Brain Commun.* 1 (2019), <https://doi.org/10.1093/braincomms/fcz022>.
- [63] Y. Wang, et al., The V3 Loop of HIV-1 Env Determines Viral Susceptibility to IFITM3 Impairment of Viral Infectivity, *J. Virol.* 91 (2017), <https://doi.org/10.1128/jvi.02441-16>.
- [64] J.K. Lim, et al., Genetic variation in OAS1 is a risk factor for initial infection with West Nile virus in man, *PLoS Pathog.* 5 (2009), e1000321, <https://doi.org/10.1371/journal.ppat.1000321>.

- [65] M.Y. Li, et al., Lyn kinase regulates egress of flaviviruses in autophagosome-derived organelles, *Nat. Commun.* 11 (2020) 5189, <https://doi.org/10.1038/s41467-020-19028-w>.
- [66] M.J. Nicholl, L.H. Robinson, C.M. Preston, Activation of cellular interferon-responsive genes after infection of human cells with herpes simplex virus type 1, *J. Gen. Virol.* 81 (2000) 2215–2218, <https://doi.org/10.1099/0022-1317-81-9-2215>.
- [67] W.A. Eimer, et al., Alzheimer's disease-associated β -amyloid is rapidly seeded by herpesviridae to protect against brain infection, *Neuron* 99 (2018) 56–63, <https://doi.org/10.1016/j.neuron.2018.06.030>, e53.
- [68] D. Idrees, V. Kumar, SARS-CoV-2 spike protein interactions with amyloidogenic proteins: potential clues to neurodegeneration, *Biochem. Biophys. Res. Commun.* 554 (2021) 94–98, <https://doi.org/10.1016/j.bbrc.2021.03.100>.
- [69] J.T. Hsu, et al., The effects of A β (1-42) binding to the SARS-CoV-2 spike protein S1 Subunit And Angiotensin-Converting Enzyme 2, *Int. J. Mol. Sci.* 22 (2021), <https://doi.org/10.3390/ijms22158226>.
- [70] A. Ramani, et al., SARS-CoV-2 targets neurons of 3D human brain organoids, *EMBO J.* 39 (2020), e106230, <https://doi.org/10.15252/embj.2020106230>.
- [71] D.E. Gordon, et al., Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms, *Science* 370 (2020), <https://doi.org/10.1126/science.abe9403>.
- [72] Y. Zhou, et al., Network medicine links SARS-CoV-2/COVID-19 infection to brain microvascular injury and neuroinflammation in dementia-like cognitive impairment, *Alzheimers Res. Ther.* 13 (2021) 110, <https://doi.org/10.1186/s13195-021-00850-3>.
- [73] C.L. Kuo, et al., APOE e4 genotype predicts severe COVID-19 in the UK biobank community cohort, *J. Gerontol. A Biol. Sci. Med. Sci.* 75 (2020) 2231–2232, <https://doi.org/10.1093/gerona/glaa131>.
- [74] W. Ni, et al., Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19, *Crit. Care* 24 (2020) 422, <https://doi.org/10.1186/s13054-020-03120-0>.
- [75] H.S. Yang, et al., Natural genetic variation determines microglia heterogeneity in wild-derived mouse models of Alzheimer's disease, *Cell Rep.* 34 (2021), 108739, <https://doi.org/10.1016/j.celrep.2021.108739>.